Speciality Medicines Ltd (SPML) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Speciality Medicines Ltd on NSE and BSE, with an AI summary of each filing.
We hereby submit Voting Results and Consolidated Scrutinizer report of the 5th AGM of the Company.
Annual General Meeting · 28 Sept 2026, 8:54 pm
We hereby submit Proceedings of 5th AGM of the Company.
Annual General Meeting · 28 Sept 2026, 6:02 pm
We hereby Submit Annual Report of FY 2025-26.
Others (Uncategorized) · 04 Sept 2026, 1:15 am
We hereby submit Notice of 5th AGM to be held on September 28, 2026.
Extra Ordinary General Meeting · 04 Sept 2026, 1:12 am
We hereby submit Outcome of the board meeting held on September 03, 2026
Others (Uncategorized) · 03 Sept 2026, 9:20 pm
Speciality Medicines Approves FY26 Directors' Report and Schedules 5th AGM Speciality Medicines Limited's board met on 3rd Sep'26 to approve the Draft Directors' Report for FY25-26. The company scheduled its 5th Annual General Meeting (AGM) for 28th Sep'26 via video conferencing. The cut-off date to determine e-voting eligibility is 21st Sep'26. Share transfer books will remain open as all shareholdings are entirely dematerialized. NSDL has been appointed as the remote e-voting agency, and CS Hardikkumar Jetani will act as the scrutinizer to ensure a fair e-voting process for the upcoming AGM.
We hereby submit intimation regarding approval for Two new products in Ethiopia.
Others (Uncategorized) · 12 Aug 2026, 10:37 pm
Speciality Medicines Secures Ethiopian Approval for Two Formulations Speciality Medicines (SPML) announced on 12 Aug'26 that it received regulatory approval from Ethiopian health authorities for two new products: Olanzapine 5 mg (Olazyn 5) and Diazepam 5 mg (Diazem 5). This approval expands the company's registered product portfolio in Ethiopia to 12 formulations, strengthening its presence in a key export market. The company continues to advance its international portfolio, which also includes two registered products in Peru, reinforcing its export-focused strategy across semi-regulated global markets.
We hereby submit Press Release titled "Speciality Medicines Limited Secures Regulatory Approval for Two New Products in Ethiopia".
Press Release · 12 Aug 2026, 10:33 pm
Speciality Medicines Secures Regulatory Approval for Two New Products in Ethiopia Speciality Medicines (SPML) received regulatory approval on 12th Aug'26 for two new products in Ethiopia: Olanzapine Tablets 5 mg (antipsychotic) and Diazepam Tablets 5 mg (anxiolytic). These approvals, valid for five years, expand the company's CNS portfolio and strengthen its presence in the African market. This brings the total registered products in Ethiopia to 12, adding to its existing two registrations in Peru. The move reinforces SPML's international registration strategy and export-led growth across key semi-regulated markets.
We hereby submit the Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 regarding Appointment of Investor and Public Relations agency of the Company.
Others (Uncategorized) · 04 Aug 2026, 11:58 pm
Speciality Medicines Appoints Capital Bridge Advisory for Investor Relations Speciality Medicines Limited (SPML) has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations agency, effective 04 Aug'26. The move aims to enhance SPML's capital market communication, strengthen its investor relations framework, and foster deeper engagement with institutional and retail investors. This appointment signals a strategic effort by the company to improve transparency and communication with the investment community, aligning with evolving stakeholder expectations.
We hereby submit Financial Results for the Half Year and Year ended March 31, 2026.
Financial Result · 28 May 2026, 10:57 pm
Speciality Medicines FY26 Results Show Strong Profit and Revenue Growth For FY26, Speciality Medicines reported a net profit of ₹1,303.29 lakh, an 81.1% YoY increase from ₹719.63 lakh in FY25. Revenue from operations grew 29.2% YoY to ₹7,528.51 lakh. For the half-year ending Mar'26 (H2FY26), net profit was ₹818.27 lakh, up 205% YoY from ₹268.36 lakh, while revenue stood at ₹4,478.34 lakh, a 45.4% YoY increase. The full-year EPS for FY26 was ₹20.11, compared to ₹11.79 in the previous year. The company completed its IPO in Mar'26.
We hereby submit the Outcome of Board Meeting held On May 28, 2026.
Outcome · 28 May 2026, 10:37 pm
Speciality Medicines Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 4,478 (+45.4% YoY | +46.8% QoQ) ■ EBITDA: 835 (+89.2% YoY | +56.5% QoQ) ■ EBITDA Margin (%): 18.6 (+431 bps YoY | +115 bps QoQ) ■ PAT: 818 (+204.9% YoY | +68.7% QoQ) ■ EPS (INR): 12.5 (+200.7% YoY | +66.3% QoQ)
Speciality Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve 1. Audited Standalone ....
Intimation · 28 May 2026, 5:30 am
Speciality Medicines Schedules Board Meeting for FY26 Financial Results Speciality Medicines (BSE: 544738) has scheduled a board meeting on 28 May'26 to consider and approve audited standalone financial statements and results for the half-year and full-year ended 31 Mar'26. The trading window for insiders has been closed since 01 Apr'26 and will reopen 48 hours after the results are declared. This meeting is crucial for assessing the company's full-year financial performance.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Niraj Shah
Acquisition/ Disposal of Shares · 19 May 2026, 3:29 pm
Niraj Shah Acquires 6.22% Stake in Speciality Medicines Niraj Rajnikant Shah has acquired a 6.22% stake in Speciality Medicines Ltd through an open market transaction. The acquisition involved 5,47,000 shares, increasing his holding from nil to 6.22% of the company's total and diluted share capital. The transactions occurred between Mar 30, '26, and May 14, '26. This disclosure was made on May 18, '26, under SEBI's substantial acquisition regulations. After the purchase, the company's equity share capital remains at Rs. 8,78,57,960, comprising 87,85,796 shares of Rs. 10 each.